A method for treating liver cancer, particularly in subjects exhibiting homologous recombination deficiency (HRD) positivity, includes using hydroxyureamethyl acylfulvene. The compound can be administered as a monotherapy or in combination with other chemotherapeutic agents and/or radiotherapy.
Disclosed are systems and methods that provide a novel framework for decision intelligence (DI)-based drug determinations. The disclosed framework can leverage a dynamically and recursively trained artificial intelligence/machine learning (AI/ML) ensemble configuration to analyze genomic data and functions that arrive from the same. Ensemble determinations and applications can increase the accuracy of the training, validation, and external testing sets associated with drug discovery and personalization. The ensemble-based computerized framework can be configured for analysis of samples using an ensemble algorithm trained with a binary mutation data and a hierarchical clustering data, which can enable determinations of drug efficacy and patent stratification.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 50/30 - Data warehousingComputing architectures
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
3.
TREATING CANCERS WITH COMBINATIONS OF ANTI-CD20 ANTIBODY AND ACYLFULVENES
A method of treating cancer includes administering a combination of active agents comprising a therapeutically effective amount of an acylfulvene, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an anti-CD20 antibody. The anti-CD20 antibody can be selected from rituximab, obinutuzumab, ofatumumab, and tositumomab. The cancer may be a B-cell cancer.
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 275/26 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a spironolactone or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.
This application discloses methods for treating a cancer that has metastasized to the brain in a subject using a therapeutically effective amount of HydroxyUreaMethyl Acylfulvene. In addition, pharmaceutical compositions having HydroxyUreaMethyl Acylfulvene and a pharmaceutically acceptably carrier, diluent, excipient, or a combination thereof are disclosed.
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
6.
MACHINE LEARNING SYSTEM AND METHOD FOR PREDICTING BLOOD BRAIN BARRIER PERMEABILITY
A machine learning system and method for predicting blood-brain barrier permeability is provided. The system obtains samples of data associated with molecules from various data sources, converts the samples into structural representations, and generates a plurality of features from the structural representations, such as fingerprint representations. Tests are executed on the features to determine blood-brain barrier permeability dependency, The system analyzes the ratio of permeable to non-permeable samples in the samples of data and augments the samples with synthetic data to create a balanced dataset if an imbalance between the types of samples is detected. The system reduces the features utilized for training the machine learning utilizing a technique, such as logistic regression, to create a selected set of features for the balanced dataset. The system trains a machine learning model using the balanced dataset and utilizing the machine learning model to predict blood-brain barrier permeability for the candidate molecule.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G06F 18/22 - Matching criteria, e.g. proximity measures
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
G06N 3/042 - Knowledge-based neural networksLogical representations of neural networks
7.
TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES
A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a PARP inhibitor or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.
The methods include treating cancer by the administration of an effective amount of acylfulvene to a subject in need thereof and an effective amount of radiation. The irradiation occurs before or concurrently with the administration of the effective amount of acylfulvene.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
This method involves treating individuals diagnosed with renal cell carcinoma using a therapeutically effective amount of hydroxyureamethyl acylfulvene. The treatment is applicable to various types of renal cell carcinoma, including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma, and medullary carcinoma.
A method for treating a subject in need thereof having a bone or blood cancer, or a cancer that metastasizes to bone that includes administering to the subject an effective amount of hydroxyureamethyl acylfulvene.
A method of treating breast cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a PARP inhibitor. Compositions and kits of the same are included herein. The breast cancer may be refractory to various PARP inhibitors.
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07C 239/18 - Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07C 275/64 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
C07C 49/573 - Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing hydroxy groups
12.
TREATING CANCERS WITH COMBINATIONS OF ACYLFULVENES WITH IBRUTINIB OR BORTEZOMIB
A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein. The cancer may be refractory to Bortezomib and/or Ibrutinib
This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.
C07C 49/573 - Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing hydroxy groups
C07C 275/64 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
14.
TREATING CANCERS WITH COMBINATIONS OF ACYLFULVENES WITH IBRUTINIB OR BORTEZOMIB
A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein. The cancer may be refractory to Bortezomib and/or Ibrutinib
The methods include treating atypical teratoid/rhabdoid tumor by administration of HydroxyUreaMethyl Acylfulvene. Some embodiments relate to treatment of atypical teratoid/rhabdoid tumor by administration of HydroxyUreaMethyl Acylfulvene to a population or subject expressing SMARCB1.
This application relates to markers for use in the determination of the sensitivity of a cancer patient to an anti-cancer agent (e.g., illudins/illudin analogs) to be administered thereto, which markers can determine whether or not the cancer of the patient has a therapeutic response to the anti-cancer agent, and to application of the markers.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
17.
COMPUTERIZED SYSTEMS AND METHODS FOR ENSEMBLE MODEL-BASED DRUG DISCOVERY
Disclosed are systems and methods that provide a novel framework for decision intelligence (DI)-based drug determinations. The disclosed framework can leverage a dynamically and recursively trained artificial intelligence / machine learning (AI/ML) ensemble configuration to analyze genomic data and functions that arrive from the same. Ensemble determinations and applications can increase the accuracy of the training, validation, and external testing sets associated with drug discovery and personalization. The ensemble-based computerized framework can be configured for analysis of samples using an ensemble algorithm trained with a binary mutation data and a hierarchical clustering data, which can enable determinations of drug efficacy and patent stratification.
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Disclosed are systems and methods that provide a novel framework for decision intelligence (DI)-based drug determinations. The disclosed framework can leverage a dynamically and recursively trained artificial intelligence / machine learning (AI/ML) ensemble configuration to analyze genomic data and functions that arrive from the same. Ensemble determinations and applications can increase the accuracy of the training, validation, and external testing sets associated with drug discovery and personalization. The ensemble-based computerized framework can be configured for analysis of samples using an ensemble algorithm trained with a binary mutation data and a hierarchical clustering data, which can enable determinations of drug efficacy and patent stratification.
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
A method for treating cancer in a patient in which a sample of the tumor or cancer is obtained from the patient and screened for responsiveness to 2,2′-dithio-bis-ethane sulfonate analogs. The sample is treated with 2,2′-dithio-bis-ethane sulfonate analogs to determine whether one or more of a plurality of biomarkers will be expressed therein.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
20.
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.
Methods for treating brain tumor cancer by administration hydroxyureamethyl-acylfulvene. Some embodiments relate to treatment of glioblastoma by administration of hydroxyureamethyl-acylfulvene. Method also includes characterizing the subtype and genetics of the markers.
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods for treating pancreatic cancer by administration hydroxyureamethyl acylfulvene. Some embodiments relate to treatment of pancreatic cancer by administration of hydroxyureamethyl acylfulvene.
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
The methods include treating cancer by the administration of an effective amount of acylfulvene to a subject in need thereof and an effective amount of radiation. The irradiation occurs before or concurrently with the administration of the effective amount of acylfulvene.
C07C 35/37 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed ring system having three rings
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
24.
METHOD FOR TREATING CANCER WITH ACYLFULVENE AND RADIATION
The methods include treating cancer by the administration of an effective amount of acylfulvene to a subject in need thereof and an effective amount of radiation. The irradiation occurs before or concurrently with the administration of the effective amount of acylfulvene.
A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a PARP inhibitor or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.
C07C 35/22 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
C07C 49/727 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
26.
TREATING CANCERS WITH COMBINATIONS OF SPIRONOLACTONE AND ACYLFULVENES
A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a spironolactone or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
C07C 239/14 - Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a PARP inhibitor or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
C07C 35/22 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
C07C 49/727 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a spironolactone or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.
C07C 239/14 - Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
A method for treating a subject in need thereof having a bone or blood cancer, or a cancer that metastasizes to bone that includes administering to the subject an effective amount of hydroxyureamethyl acylfulvene.
C07C 275/04 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
A method for treating a subject in need thereof having a bone or blood cancer, or a cancer that metastasizes to bone that includes administering to the subject an effective amount of hydroxyureamethyl acylfulvene.
C07C 275/04 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
A method of treating NSCLC or lung cancer in an individual including administering to the individual an effective amount of a composition comprising nanomolar potent particles comprising acylfulvene. The treatment can be based upon the individual having squamous cellular carcinoma. Another aspect includes compositions (such as pharmaceutical compositions), medicine, kits, and unit dosages useful for the methods described herein.
C07C 49/755 - Unsaturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A method of treating NSCLC or lung cancer in an individual including administering to the individual an effective amount of a composition comprising nanomolar potent particles comprising acylfulvene. The treatment can be based upon the individual having squamous cellular carcinoma. Another aspect includes compositions (such as pharmaceutical compositions), medicine, kits, and unit dosages useful for the methods described herein.
This application discloses methods for treating a cancer that has metastasized to the brain in a subject using a therapeutically effective amount of HydroxyUreaMethyl Acylfulvene. In addition, pharmaceutical compositions having HydroxyUreaMethyl Acylfulvene and a pharmaceutically acceptably carrier, diluent, excipient, or a combination thereof are disclosed.
This application discloses methods for treating a cancer that has metastasized to the brain in a subject using a therapeutically effective amount of HydroxyUreaMethyl Acylfulvene. In addition, pharmaceutical compositions having HydroxyUreaMethyl Acylfulvene and a pharmaceutically acceptably carrier, diluent, excipient, or a combination thereof are disclosed.
The methods include treating atypical teratoid/rhabdoid tumor by administration of HydroxyUreaMethyl Acylfulvene. Some embodiments relate to treatment of atypical teratoid/rhabdoid tumor by administration of HydroxyUreaMethyl Acylfulvene to a population or subject expressing SMARCB1.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
C07C 49/727 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
C07C 35/37 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed ring system having three rings
C07C 49/755 - Unsaturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
The methods include treating atypical teratoid/rhabdoid tumor by administration of HydroxyUreaMethyl Acylfulvene. Some embodiments relate to treatment of atypical teratoid/rhabdoid tumor by administration of HydroxyUreaMethyl Acylfulvene to a population or subject expressing SMARCB1.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
C07C 35/37 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed ring system having three rings
C07C 49/727 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
C07C 49/755 - Unsaturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
37.
METHOD FOR TREATING FEMALE NON-SMOKERS WITH NON-SMALL CELL LUNG CANCER
A method of treating a female patient suffering from non-small cell lung cancer includes the step of administering to the patient in need thereof a composition of 2,2′-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof. The method can include other primary line therapies.
This application relates to markers for use in the determination of the sensitivity of a cancer patient to an anti-cancer agent (e.g., illudins/illudin analogs) to be administered thereto, which markers can determine whether or not the cancer of the patient has a therapeutic response to the anti-cancer agent, and to application of the markers.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
This application relates to markers for use in the determination of the sensitivity of a cancer patient to an anti-cancer agent (e.g., illudins/illudin analogs) to be administered thereto, which markers can determine whether or not the cancer of the patient has a therapeutic response to the anti-cancer agent, and to application of the markers.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
42 - Scientific, technological and industrial services, research and design
Goods & Services
Drug discovery services; pharmaceutical research and
development services in the field of oncology;
pharmaceutical drug discovery services in the field of
oncology; scientific and medical research and development
for pharmaceuticals, pharmaceutical preparations and
substances in the field of oncology.
Methods for treating pancreatic cancer by administration hydroxyureamethyl acylfulvene. Some embodiments relate to treatment of pancreatic cancer by administration of hydroxyureamethyl acylfulvene.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Methods for treating pancreatic cancer by administration hydroxyureamethyl acylfulvene. Some embodiments relate to treatment of pancreatic cancer by administration of hydroxyureamethyl acylfulvene.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
42 - Scientific, technological and industrial services, research and design
Goods & Services
Drug discovery services; pharmaceutical research and
development services in the field of oncology;
pharmaceutical drug discovery services in the field of
oncology; scientific and medical research and development
for pharmaceuticals, pharmaceutical preparations and
substances in the field of oncology.
44.
HYDROXYUREAMETHYL-ACYLFULVENE FOR TREATING BRAIN CANCER OR CNS CANCER
Methods for treating brain tumor cancer by administration hydroxyureamethyl-acylfulvene. Some embodiments relate to treatment of glioblastoma by administration of hydroxyureamethyl-acylfulvene. Method also includes characterizing the subtype and genetics of the markers.
C07C 35/37 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed ring system having three rings
C07C 49/727 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
C07C 49/755 - Unsaturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
45.
HYDROXYUREAMETHYL-ACYLFULVENE FOR TREATING BRAIN CANCER OR CNS CANCER
Methods for treating brain tumor cancer by administration hydroxyureamethyl-acylfulvene. Some embodiments relate to treatment of glioblastoma by administration of hydroxyureamethyl-acylfulvene. Method also includes characterizing the subtype and genetics of the markers.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
C07C 35/37 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed ring system having three rings
C07C 49/727 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
C07C 49/755 - Unsaturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Drug discovery services; pharmaceutical research and development services in the field of oncology; pharmaceutical drug discovery services in the field of oncology; scientific and medical research and development for pharmaceuticals, pharmaceutical preparations and substances in the field of oncology.
47.
Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers
Methods for determining the likelihood that a subject suffering from a solid tumor cancer will benefit from treatment with an illudin are disclosed herein. Further, there are also methods for treatment based on such determination. In several embodiments, markers prostaglandin reductase 1 (PTGR1), Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14), Aspartate Beta-Hydroxylase (ASPH) together with one or more genes or alone may be used to enhance or guide treatment with an illudin. In certain embodiments, the protein or gene may be expressed or methylated.
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
C12Q 1/42 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving phosphatase
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
48.
METHOD FOR DETERMINING SENSITIVITY TO 2,2'-DITHIO-BIS-ETHANE SULFONATE
A method for treating cancer in a patient in which a sample of the tumor or cancer is obtained from the patient and screened for responsiveness to 2,2'-dithio-bis-ethane sulfonate analogs. The sample is treated with 2,2'-dithio-bis-ethane sulfonate analogs to determine whether one or more of a plurality of biomarkers will be expressed therein.
A method for treating cancer in a patient in which a sample of the tumor or cancer is obtained from the patient and screened for responsiveness to 2,2'-dithio-bis-ethane sulfonate analogs. The sample is treated with 2,2'-dithio-bis-ethane sulfonate analogs to determine whether one or more of a plurality of biomarkers will be expressed therein.
This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.
C07C 275/64 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
C07C 49/573 - Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing hydroxy groups
42 - Scientific, technological and industrial services, research and design
Goods & Services
Drug discovery services; pharmaceutical research and development services in the field of oncology; pharmaceutical drug discovery services in the field of oncology; scientific and medical research and development for pharmaceuticals, pharmaceutical preparations and substances in the field of oncology
52.
METHOD FOR TREATING FEMALE NON-SMOKERS WITH NON-SMALL CELL LUNG CANCER
A method of treating a female patient suffering from non-small cell lung cancer includes the step of administering to the patient in need thereof a composition of 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof. The method can include other primary line therapies.
A method of treating a female patient suffering from non-small cell lung cancer includes the step of administering to the patient in need thereof a composition of 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof. The method can include other primary line therapies.
A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
42 - Scientific, technological and industrial services, research and design
Goods & Services
Drug discovery services; pharmaceutical research and
development services in the field of oncology;
pharmaceutical drug discovery services in the field of
oncology; scientific and medical research and development
for pharmaceuticals, pharmaceutical preparations and
substances in the field of oncology.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Drug discovery services; pharmaceutical research and
development services in the field of oncology;
pharmaceutical drug discovery services in the field of
oncology; scientific and medical research and development
for pharmaceuticals, pharmaceutical preparations and
substances in the field of oncology.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical drug development services; pharmaceutical research and development services in the field of oncology; scientific and medical research and development for pharmaceuticals, pharmaceutical preparations and substances in the field of oncology.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical drug development services; pharmaceutical research and development services in the field of oncology; scientific and medical research and development for pharmaceuticals, pharmaceutical preparations and substances in the field of oncology.
42 - Scientific, technological and industrial services, research and design
Goods & Services
drug discovery services; pharmaceutical research and development services in the field of oncology; pharmaceutical drug discovery services in the field of oncology; scientific and medical research and development for pharmaceuticals, pharmaceutical preparations and substances in the field of oncology
59.
METHODS FOR THE TREATMENT OF SOLID TUMOR CANCERS USING ILLUDINS AND BIOMARKERS
Methods for determining the likelihood that a subject suffering from a solid tumor cancer will benefit from treatment with an illudin are disclosed herein. Further, there are also methods for treatment based on such determination. In several embodiments, markers prostaglandin reductase 1 (PTGR1), Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14), Aspartate Beta- Hydroxylase (ASPH) together with one or more genes or alone may be used to enhance or guide treatment with an illudin. In certain embodiments, the protein or gene may be expressed or methylated.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
C07C 239/14 - Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
Methods for determining the likelihood that a subject suffering from a solid tumor cancer will benefit from treatment with an illudin are disclosed herein. Further, there are also methods for treatment based on such determination. In several embodiments, markers prostaglandin reductase 1 (PTGR1), Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14), Aspartate Beta- Hydroxylase (ASPH) together with one or more genes or alone may be used to enhance or guide treatment with an illudin. In certain embodiments, the protein or gene may be expressed or methylated.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
C07C 239/14 - Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
C07C 49/743 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
C07C 275/64 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
62.
ILLUDIN ANALOGS, USES THEREOF, AND METHODS FOR SYNTHESIZING THE SAME
This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
C07C 35/37 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed ring system having three rings
C07C 49/727 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
C07C 49/755 - Unsaturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
42 - Scientific, technological and industrial services, research and design
Goods & Services
drug discovery services; pharmaceutical research and development services in the field of oncology; pharmaceutical drug discovery services in the field of oncology; scientific and medical research and development for pharmaceuticals, pharmaceutical preparations and substances in the field of oncology
42 - Scientific, technological and industrial services, research and design
Goods & Services
drug discovery services; pharmaceutical research and development services in the field of oncology; pharmaceutical drug discovery services in the field of oncology; scientific and medical research and development for pharmaceuticals, pharmaceutical preparations and substances in the field of oncology
65.
Increasing cancer patient survival time by administration of dithio-containing compounds
The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
